Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025.

Q4 2024 Earnings Call Transcript March 13, 2025 aTyr Pharma, Inc. beats earnings expectations. Reported EPS is $-0.18, expectations were $-0.23. Operator: Good afternoon, ladies and gentlemen, and ...

Topline data from Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025. Fourth positive DSMB review for efzofitimod in Phase 3 EFZO-FIT study reinforces ...

And we continue to interrogate other tRNA synthetase fragments to identify ... we are not in a formal open label type extension. So, I’m very pleased with the progress. I think it’s a great ...

The purified antibodies were labeled with either AGAFDADPLVVEI peptide or AGAFDADPLVVEI ... Shown are SDS-PAGE time course analyses of ligation reactions using Lysine-tRNA ligase (LysS; C-terminal ...

Alternative splicing (AS) of pre-mRNA plays a crucial role in tissue-specific gene regulation, with disease implications due to splicing defects. Predicting and manipulating AS can therefore uncover ...

Peer-reviewed publication validates efzofitimod's unique anti-inflammatory mechanism of action on macrophages through neuropilin-2 (NRP2) receptor.<p ...

With $75.1 million in cash and minimal competition, aTyr Pharma is well-positioned financially, making it a compelling ...

The US Food and Drug Administration’s new standards for foods before they can be labeled as “healthy” on their packaging will go into effect about two months later than planned, according to ...